Indication
B-cell malignancies, autoimmune diseases.
Product schedules
Phase I dose-escalation trial in lymphoma completed;
Well-tolerated in lymphoma patients; efficacy demonstrated in relapse and resistant lymphoma patients.
Molecular characteristics
One of the B-cell surface markers, highly expressed on various B-cell malignancies.
The expression profile during B-cell differentiation stages is similar to that CD20.
One of the B-cell surface markers, highly expressed on various B-cell malignancies
The expression profile during B-cell differentiation stages is similar to that CD20;High potential for successful clinical development, in context that the safety of B-cell targeted therapy has been validated by Rituximab
ESG-206 is a First-In-Class drug that can effectively address the high relapse rate and drug resistance issues associated with existing drugs/therapies such as CD20 monoclonal antibodies, BTK inhibitors, and CAR-T therapies. It also has the potential to become a breakthrough therapy and advance into frontlinie treatment
NHP toxicology studies show excellent safety, with an HNSTD of 100 mg/kg
